Indian Pharma Resilient to Trump’s Generic Drug Tariff Threats

Trump’s threat to impose steep tariffs on imported generic drugs is unlikely to significantly impact Indian pharmaceutical companies. Former President Donald Trump proposed a 100% levy by 2028, escalating to 200% a year later, unless production shifts to the United States. Indian firms such as Sun Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd. are advised to maintain current operations as these duties may not fully materialize due to substantial commercial and political challenges.

Understanding the Proposed Tariffs

Former President Donald Trump has outlined a plan targeting off-patent medications imported into the United States. This proposal involves a significant increase in import duties over two years. The intent is to compel foreign manufacturers to relocate their production facilities to American soil.

• A 100% tariff would be imposed on imported generic drugs by 2028.
• This tariff would then escalate to 200% a year later.

The Economic Role of Generic Medicines

Generic drugs are fundamental to the US healthcare system, playing a critical role in reducing prescription costs. These affordable alternatives become available once branded drug patents expire, fostering competition and lowering prices. For instance, the price of the HIV medicine Truvada dramatically decreased following the introduction of generic versions.

• The price of Truvada dropped from approximately $50 to $3 per tablet.
• Off-patent medicines account for over 90% of US prescriptions.
• They represent only a small fraction of overall prescription drug spending.

Challenges for Generic Drug Producers

Generic drug manufacturers typically operate on a business model characterized by high production volumes and very narrow profit margins. This economic reality makes it difficult for them to absorb significant additional costs such as tariffs. Relocating extensive manufacturing operations to the United States would also present substantial financial and logistical hurdles.

• Asia’s top five generic players have an average EBITDA margin of about 22%.
• This margin is considerably lower than that of innovative drugmakers.

Commercial and Political Roadblocks

Implementing such tariffs would likely result in American patients and the broader healthcare system facing higher expenses, potentially fueling inflation. Furthermore, if these increased costs cannot be passed on to consumers, some essential generic drugs might become unprofitable to produce. This situation could lead to critical drug shortages, an outcome even less desirable than inflated prices.

• Healthcare analysts estimate tariffs could raise total prescription-drug spending by 8% to 15%.

A policy that makes affordable medicines more expensive or unavailable would be politically unpopular. This would be particularly true in 2028, which is a presidential election year, adding another layer of complexity to the tariff proposal’s feasibility.

India’s Generics Industry: A Global Leader

India’s pharmaceutical industry has a long history of developing expertise in reverse-engineering Western medicines. This capability was significantly bolstered by a 1970 decision to abolish pharmaceutical product patents, fostering a strong domestic manufacturing base. By 2005, India had achieved the necessary scale to emerge as a global leader in the export of off-patent drugs, a position reinforced by a 1984 US law that streamlined FDA approval for generics.

The historical context also reveals challenges for US manufacturing by Indian firms. Dr. Reddy’s, for example, previously closed a generic-drug factory in Louisiana after experiencing years of financial losses there. This demonstrates the economic difficulties associated with operating such facilities within the United States.

Strategic US Investments, Not Tariff Responses

While some Indian pharmaceutical companies have indeed invested in manufacturing facilities within the United States, these moves are primarily strategic. Companies like Sun Pharmaceutical and Aurobindo Pharma Ltd. often target higher-margin treatments with these investments. They are not typically driven by or intended as a direct response to potential tariff threats.

Concerns in Washington about over-reliance on foreign suppliers for essential drugs are valid and widely acknowledged. However, tariffs are generally considered an imprecise instrument for addressing these complex supply chain vulnerabilities. More effective strategies for enhancing resilience and securing supply chains would involve targeted incentives for strategically important medicines, fostering diversified supply chains, and establishing guaranteed purchasing contracts, rather than broadly taxing all imported generics.

The United States has long benefited from a healthcare system prioritizing affordable and safe medicines. Disrupting this framework through broad tariffs risks undermining decades of progress. This could impact access to crucial medications for its citizens.